Skip to main content
Top
Published in: Diabetologia 5/2017

Open Access 01-05-2017 | Article

Serum magnesium and the risk of prediabetes: a population-based cohort study

Authors: Brenda C. T. Kieboom, Symen Ligthart, Abbas Dehghan, Steef Kurstjens, Jeroen H. F. de Baaij, Oscar H. Franco, Albert Hofman, Robert Zietse, Bruno H. Stricker, Ewout J. Hoorn

Published in: Diabetologia | Issue 5/2017

Login to get access

Abstract

Aims/hypothesis

Previous studies have found an association between serum magnesium and incident diabetes; however, this association may be due to reverse causation, whereby diabetes may induce urinary magnesium loss. In contrast, in prediabetes (defined as impaired fasting glucose), serum glucose levels are below the threshold for urinary magnesium wasting and, hence, unlikely to influence serum magnesium levels. Thus, to study the directionality of the association between serum magnesium levels and diabetes, we investigated its association with prediabetes. We also investigated whether magnesium-regulating genes influence diabetes risk through serum magnesium levels. Additionally, we quantified the effect of insulin resistance in the association between serum magnesium levels and diabetes risk.

Methods

Within the population-based Rotterdam Study, we used Cox models, adjusted for age, sex, lifestyle factors, comorbidities, kidney function, serum levels of electrolytes and diuretic use, to study the association between serum magnesium and prediabetes/diabetes. In addition, we performed two mediation analyses: (1) to study if common genetic variation in eight magnesium-regulating genes influence diabetes risk through serum magnesium levels; and (2) to quantify the proportion of the effect of serum magnesium levels on diabetes that is mediated through insulin resistance (quantified by HOMA-IR).

Results

A total of 8555 participants (mean age, 64.7 years; median follow-up, 5.7 years) with normal glucose levels (mean ± SD: 5.46 ± 0.58 mmol/l) at baseline were included. A 0.1 mmol/l decrease in serum magnesium level was associated with an increase in diabetes risk (HR 1.18 [95% CI 1.04, 1.33]), confirming findings from previous studies. Of interest, a similar association was found between serum magnesium levels and prediabetes risk (HR 1.12 [95% CI 1.01, 1.25]). Genetic variation in CLDN19, CNNM2, FXYD2, SLC41A2, and TRPM6 significantly influenced diabetes risk (p < 0.05), and for CNNM2, FXYD2, SLC41A2 and TRPM6 this risk was completely mediated by serum magnesium levels. We found that 29.1% of the effect of serum magnesium levels on diabetes was mediated through insulin resistance, whereas for prediabetes 13.4% was mediated through insulin resistance.

Conclusions/interpretation

Low serum magnesium levels are associated with an increased risk of prediabetes and this increased risk is similar to that of diabetes. Furthermore, common variants in magnesium-regulating genes modify diabetes risk through serum magnesium levels. Both findings support a potential causal role of magnesium in the development of diabetes, where the hypothesised pathway is partly mediated through insulin resistance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ligthart S, van Herpt TT, Leening MJ et al (2015) Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 4:44–51CrossRefPubMed Ligthart S, van Herpt TT, Leening MJ et al (2015) Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 4:44–51CrossRefPubMed
2.
go back to reference Yajnik CS, Smith RF, Hockaday TD, Ward NI (1984) Fasting plasma magnesium concentrations and glucose disposal in diabetes. Br Med J (Clin Res Ed) 288:1032–1034CrossRef Yajnik CS, Smith RF, Hockaday TD, Ward NI (1984) Fasting plasma magnesium concentrations and glucose disposal in diabetes. Br Med J (Clin Res Ed) 288:1032–1034CrossRef
3.
go back to reference Barbagallo M, Dominguez LJ, Galioto A et al (2003) Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Asp Med 24:39–52CrossRef Barbagallo M, Dominguez LJ, Galioto A et al (2003) Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Asp Med 24:39–52CrossRef
4.
go back to reference Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R (1993) Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 21:1024–1029CrossRefPubMed Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R (1993) Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 21:1024–1029CrossRefPubMed
5.
go back to reference Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H (2007) Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 167:956–965CrossRefPubMed Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H (2007) Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 167:956–965CrossRefPubMed
6.
go back to reference Song Y, Manson JE, Buring JE, Liu S (2004) Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 27:59–65CrossRefPubMed Song Y, Manson JE, Buring JE, Liu S (2004) Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 27:59–65CrossRefPubMed
7.
go back to reference Kim DJ, Xun P, Liu K et al (2010) Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 33:2604–2610CrossRefPubMedPubMedCentral Kim DJ, Xun P, Liu K et al (2010) Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 33:2604–2610CrossRefPubMedPubMedCentral
8.
go back to reference Lopez-Ridaura R, Willett WC, Rimm EB et al (2004) Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 27:134–140CrossRefPubMed Lopez-Ridaura R, Willett WC, Rimm EB et al (2004) Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 27:134–140CrossRefPubMed
9.
go back to reference Hruby A, Meigs JB, O’Donnell CJ, Jacques PF, McKeown NM (2014) Higher magnesium intake reduces risk of impaired glucose and insulin metabolism and progression from prediabetes to diabetes in middle-aged Americans. Diabetes Care 37:419–427CrossRefPubMedPubMedCentral Hruby A, Meigs JB, O’Donnell CJ, Jacques PF, McKeown NM (2014) Higher magnesium intake reduces risk of impaired glucose and insulin metabolism and progression from prediabetes to diabetes in middle-aged Americans. Diabetes Care 37:419–427CrossRefPubMedPubMedCentral
10.
go back to reference Rodriguez-Moran M, Simental Mendia LE, Zambrano Galvan G, Guerrero-Romero F (2011) The role of magnesium in type 2 diabetes: a brief based-clinical review. Magnes Res 24:156–162PubMed Rodriguez-Moran M, Simental Mendia LE, Zambrano Galvan G, Guerrero-Romero F (2011) The role of magnesium in type 2 diabetes: a brief based-clinical review. Magnes Res 24:156–162PubMed
11.
go back to reference Hopping BN, Erber E, Grandinetti A, Verheus M, Kolonel LN, Maskarinec G (2010) Dietary fiber, magnesium, and glycemic load alter risk of type 2 diabetes in a multiethnic cohort in Hawaii. J Nutr 140:68–74CrossRefPubMedPubMedCentral Hopping BN, Erber E, Grandinetti A, Verheus M, Kolonel LN, Maskarinec G (2010) Dietary fiber, magnesium, and glycemic load alter risk of type 2 diabetes in a multiethnic cohort in Hawaii. J Nutr 140:68–74CrossRefPubMedPubMedCentral
12.
go back to reference Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL (1999) Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 159:2151–2159CrossRefPubMed Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL (1999) Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 159:2151–2159CrossRefPubMed
13.
14.
go back to reference Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH (2016) Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes 65:3–13CrossRefPubMed Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH (2016) Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes 65:3–13CrossRefPubMed
17.
go back to reference Leening MJ, Kavousi M, Heeringa J et al (2012) Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 27:173–185CrossRefPubMedPubMedCentral Leening MJ, Kavousi M, Heeringa J et al (2012) Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 27:173–185CrossRefPubMedPubMedCentral
18.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
19.
go back to reference Meyer TE, Verwoert GC, Hwang SJ et al (2010) Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six loci influencing serum magnesium levels. PLoS Genet 6, e1001045CrossRefPubMedPubMedCentral Meyer TE, Verwoert GC, Hwang SJ et al (2010) Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six loci influencing serum magnesium levels. PLoS Genet 6, e1001045CrossRefPubMedPubMedCentral
20.
go back to reference Chan KH, Chacko SA, Song Y et al (2015) Genetic variations in magnesium-related ion channels may affect diabetes risk among African American and Hispanic American women. J Nutr 145:418–424CrossRefPubMedPubMedCentral Chan KH, Chacko SA, Song Y et al (2015) Genetic variations in magnesium-related ion channels may affect diabetes risk among African American and Hispanic American women. J Nutr 145:418–424CrossRefPubMedPubMedCentral
21.
go back to reference Song Y, Hsu YH, Niu T, Manson JE, Buring JE, Liu S (2009) Common genetic variants of the ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women. BMC Med Genet 10:4CrossRefPubMedPubMedCentral Song Y, Hsu YH, Niu T, Manson JE, Buring JE, Liu S (2009) Common genetic variants of the ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women. BMC Med Genet 10:4CrossRefPubMedPubMedCentral
23.
go back to reference Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34:816–834CrossRefPubMedPubMedCentral Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34:816–834CrossRefPubMedPubMedCentral
25.
go back to reference Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14:1707–1723CrossRefPubMed Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14:1707–1723CrossRefPubMed
26.
go back to reference Baron RM, Kenny DA (1986) The moderator mediator variable distinction in social psychological-research—conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173–1182CrossRefPubMed Baron RM, Kenny DA (1986) The moderator mediator variable distinction in social psychological-research—conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173–1182CrossRefPubMed
27.
go back to reference Hayes AF (2009) Beyond Baron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr 76:408–420CrossRef Hayes AF (2009) Beyond Baron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr 76:408–420CrossRef
28.
go back to reference Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data Via Em Algorithm. J Roy Stat Soc B Met 39:1–38 Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data Via Em Algorithm. J Roy Stat Soc B Met 39:1–38
29.
go back to reference Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M et al (2015) Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis 66:775–782CrossRefPubMed Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M et al (2015) Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis 66:775–782CrossRefPubMed
30.
go back to reference Tosiello L (1996) Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 156:1143–1148CrossRefPubMed Tosiello L (1996) Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 156:1143–1148CrossRefPubMed
31.
go back to reference Imai K, Keele L, Tingley D (2010) A general approach to causal mediation analysis. Psychol Methods 15:309–334CrossRefPubMed Imai K, Keele L, Tingley D (2010) A general approach to causal mediation analysis. Psychol Methods 15:309–334CrossRefPubMed
32.
go back to reference Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y (2007) Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 20:237–244PubMed Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y (2007) Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 20:237–244PubMed
33.
go back to reference Gunther T (2010) The biochemical function of Mg2+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes Res 23:5–18PubMed Gunther T (2010) The biochemical function of Mg2+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes Res 23:5–18PubMed
34.
go back to reference Song Y, He K, Levitan EB, Manson JE, Liu S (2006) Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 23:1050–1056CrossRefPubMed Song Y, He K, Levitan EB, Manson JE, Liu S (2006) Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 23:1050–1056CrossRefPubMed
35.
go back to reference Rodriguez-Moran M, Guerrero-Romero F (2003) Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 26:1147–1152CrossRefPubMed Rodriguez-Moran M, Guerrero-Romero F (2003) Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 26:1147–1152CrossRefPubMed
36.
go back to reference Mooren FC, Kruger K, Volker K, Golf SW, Wadepuhl M, Kraus A (2011) Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 13:281–284CrossRefPubMed Mooren FC, Kruger K, Volker K, Golf SW, Wadepuhl M, Kraus A (2011) Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 13:281–284CrossRefPubMed
38.
go back to reference Sahni J, Nelson B, Scharenberg AM (2007) SLC41A2 encodes a plasma-membrane Mg2+ transporter. Biochem J 401:505–513CrossRefPubMed Sahni J, Nelson B, Scharenberg AM (2007) SLC41A2 encodes a plasma-membrane Mg2+ transporter. Biochem J 401:505–513CrossRefPubMed
39.
go back to reference Claverie-Martin F (2015) Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. Clin Kidney J 8:656–664CrossRefPubMedPubMedCentral Claverie-Martin F (2015) Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. Clin Kidney J 8:656–664CrossRefPubMedPubMedCentral
40.
go back to reference Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD (2007) Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50:202–211CrossRefPubMed Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD (2007) Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50:202–211CrossRefPubMed
41.
go back to reference Meij IC, Koenderink JB, van Bokhoven H et al (2000) Dominant isolated renal magnesium loss is caused by misrouting of the Na+, K+-ATPase gamma-subunit. Nat Genet 26:265–266CrossRefPubMed Meij IC, Koenderink JB, van Bokhoven H et al (2000) Dominant isolated renal magnesium loss is caused by misrouting of the Na+, K+-ATPase gamma-subunit. Nat Genet 26:265–266CrossRefPubMed
Metadata
Title
Serum magnesium and the risk of prediabetes: a population-based cohort study
Authors
Brenda C. T. Kieboom
Symen Ligthart
Abbas Dehghan
Steef Kurstjens
Jeroen H. F. de Baaij
Oscar H. Franco
Albert Hofman
Robert Zietse
Bruno H. Stricker
Ewout J. Hoorn
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 5/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4224-4

Other articles of this Issue 5/2017

Diabetologia 5/2017 Go to the issue

Up front

Up front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.